National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Opicapone (Ongentys®). HTA ID: 20055

Opicapone (Ongentys®) is licensed as adjunctive therapy to levodopa and DOPA decarboxylase inhibitors (L-DOPA+DDCI) in adults with Parkinson’s disease and end-of-dose motor fluctuations in patients not stabilised on such combinations.

 

NCPE Assessment Process Complete
Rapid review commissioned 14/12/2020
Rapid review completed 18/01/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends opicapone not be considered for reimbursement at the submitted price*.

 

 *This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.